JP5801826B2 - ダビガトランエテキシラートを含有する経口用医薬組成物 - Google Patents
ダビガトランエテキシラートを含有する経口用医薬組成物 Download PDFInfo
- Publication number
- JP5801826B2 JP5801826B2 JP2012555381A JP2012555381A JP5801826B2 JP 5801826 B2 JP5801826 B2 JP 5801826B2 JP 2012555381 A JP2012555381 A JP 2012555381A JP 2012555381 A JP2012555381 A JP 2012555381A JP 5801826 B2 JP5801826 B2 JP 5801826B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- oral pharmaceutical
- inorganic acid
- composition according
- binder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
ダビガトランエテキシラートメシル酸塩 86.55mg
アビセル 102 78mg
リン酸二水素ナトリウム 55.00mg
リン酸 適量
HPMC 18mg
コリドン CL 8mg
アエロジル 1mg
ステアリン酸マグネシウム 1.5mg
ダビガトランエテキシラートメシル酸塩 86.55mg
Dicafos 20mg
リン酸二水素アンモニウム 70.00mg
リン酸 適量
ポビドン 25 5mg
コリドン CL 8mg
アエロジル 1mg
ステアリン酸マグネシウム 1.5mg
ダビガトランエテキシラートメシル酸塩 86.55mg
ラクトース一水和物 60mg
リン酸二水素カリウム 65.00mg
リン酸 適量
クロスカルメロース 8mg
アエロジル 1mg
ステアリン酸マグネシウム 1.5mg
ダビガトランエテキシラートメシル酸塩 86.55mg
ラクトース無水物 55mg
塩化マグネシウム六水和物 55.00mg
クロスカルメロース 8mg
アエロジル 1mg
ステアリン酸マグネシウム 1.5mg
ダビガトランエテキシラートメシル酸塩 86.55mg
微結晶セルロース(MCC) 80mg
ポビドン 25 15.00mg
塩酸 適量
コリドン CL 8mg
アエロジル 1mg
ステアリン酸マグネシウム 1.5mg
Claims (16)
- ダビガトランエテキシラートまたはその薬学的に許容される塩と無機酸添加剤とを含有する経口用医薬組成物。
- 前記無機酸添加剤の1%水溶液におけるpH値が6未満である、請求項1に記載の経口用医薬組成物。
- 前記無機酸添加剤が無機酸および/または無機酸の塩である、請求項1又は2に記載の経口用医薬組成物。
- 前記無機酸が塩酸、硫酸およびリン酸から選択される、請求項3に記載の経口用医薬組成物。
- 前記無機酸が、マイクロカプセルに封入された状態、結合剤表面に吸着した状態、または結合剤内に吸収された状態で存在する、請求項4に記載の経口用医薬組成物。
- 前記結合剤がポリマー、親水性ポリマー、およびケイ酸から選択される、請求項5に記載の経口用医薬組成物。
- 前記無機酸の塩がリン酸水素塩、リン酸二水素塩、硫酸水素塩、塩化アンモニウム、硫酸アンモニウム、硫酸マグネシウム、塩化マグネシウム、塩化第一鉄、塩化第二鉄、塩化カルシウムおよび硫酸カルシウムから選択される、請求項3に記載の経口用医薬組成物。
- 前記リン酸水素塩、リン酸二水素塩および硫酸水素塩が、アルカリ塩またはアンモニウム塩である、請求項7に記載の経口用医薬組成物。
- 前記無機酸の塩が、結合剤表面に吸着した状態、または結合剤内に吸収された状態で存在する、請求項7または8に記載の経口用医薬組成物。
- 前記結合剤がポリマー、親水性ポリマー、およびケイ酸から選択される、請求項9に記載の経口用医薬組成物。
- 前記有効成分がメシル酸塩として存在する、請求項1〜10のいずれか1項に記載の経口用医薬組成物。
- ダビガトランエテキシラートまたはその薬学的に許容される塩の含有量が、組成物の総重量に対して45重量%より高い、請求項1〜11のいずれか1項に記載の経口用医薬組成物。
- 前記無機酸添加剤を含むか該無機酸添加剤からなるコア物質と、該コア物質の周囲に形成された有効成分含有層とを含む、請求項1〜12のいずれか1項に記載の経口用医薬組成物。
- カプセル剤または錠剤である、請求項1〜13のいずれか1項に記載の経口用医薬組成物。
- 前記有効成分を前記無機酸添加剤と混合すること、およびさらなる加工工程の後に任意で、得られた混合物を圧縮成形して錠剤とするか、得られた混合物を充填してカプセル剤とすることを含む、請求項1〜14のいずれか1項に記載の経口用医薬組成物を調製する方法。
- 前記混合の前に、前記無機酸添加剤をマイクロカプセルに封入するか、結合剤表面に吸着させるか、または結合剤内に吸収させる、請求項15に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10155059 | 2010-03-01 | ||
EP10155059.8 | 2010-03-01 | ||
PCT/EP2011/052919 WO2011107427A1 (en) | 2010-03-01 | 2011-02-28 | Dabigatran etexilate-containing oral pharmaceutical composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013521244A JP2013521244A (ja) | 2013-06-10 |
JP5801826B2 true JP5801826B2 (ja) | 2015-10-28 |
Family
ID=43982233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012555381A Expired - Fee Related JP5801826B2 (ja) | 2010-03-01 | 2011-02-28 | ダビガトランエテキシラートを含有する経口用医薬組成物 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20130052262A1 (ja) |
EP (1) | EP2542224B1 (ja) |
JP (1) | JP5801826B2 (ja) |
CA (1) | CA2791561A1 (ja) |
CY (1) | CY1115556T1 (ja) |
DK (1) | DK2542224T3 (ja) |
EA (1) | EA201201202A1 (ja) |
ES (1) | ES2509117T3 (ja) |
IL (1) | IL221742A (ja) |
PL (1) | PL2542224T3 (ja) |
PT (1) | PT2542224E (ja) |
SI (1) | SI2542224T1 (ja) |
WO (1) | WO2011107427A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
ITMI20110445A1 (it) * | 2011-03-22 | 2012-09-23 | Lo Li Pharma Srl | Formulazione farmaceutica comprendente inositolo. |
CN103304539A (zh) * | 2012-03-07 | 2013-09-18 | 天津药物研究院 | 达比加群酯苹果酸盐及其制备方法和应用 |
EP2740471B1 (en) | 2012-12-07 | 2015-05-27 | Hexal AG | Oral pharmaceutical composition comprising dabigatran etexilate |
IN2013CH05441A (ja) * | 2013-11-26 | 2015-05-29 | Aurobindo Pharma Ltd | |
IN2014MU01042A (ja) | 2014-03-26 | 2015-10-02 | Cadila Healthcare Ltd | |
CN105919962B (zh) * | 2015-12-18 | 2019-01-18 | 重庆两江药物研发中心有限公司 | 一种达比加群酯片剂及其制备方法 |
CN106491553A (zh) * | 2016-12-09 | 2017-03-15 | 吉林省博大伟业制药有限公司 | 一种甲磺酸达比加群酯的新合成工艺 |
JP2019014712A (ja) * | 2017-07-03 | 2019-01-31 | エルメッド エーザイ株式会社 | 安定なダビガトラン製剤 |
CN110339193B (zh) | 2018-04-04 | 2022-04-29 | 上海汉都医药科技有限公司 | 含达比加群酯的药物组合物及其制备方法 |
JP2021014411A (ja) * | 2019-07-10 | 2021-02-12 | 日医工株式会社 | 安定なダビガトランエテキシラート製剤 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4016254A (en) * | 1972-05-19 | 1977-04-05 | Beecham Group Limited | Pharmaceutical formulations |
PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
DK1485094T4 (da) * | 2002-03-07 | 2020-06-22 | Boehringer Ingelheim Int | Doseringsform til oral indgivelse af 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsyre-ethylester eller dets salte |
US20040029774A1 (en) * | 2002-08-06 | 2004-02-12 | Aly Gamay | Composition and methods for the treatment of musculoskeletal disorders and collagen and elastin deficiencies |
GB0230034D0 (en) * | 2002-12-23 | 2003-01-29 | Biochemie Gmbh | Organic compounds |
DE10339862A1 (de) * | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
AR062057A1 (es) * | 2006-07-17 | 2008-10-15 | Boehringer Ingelheim Int | Uso de los inhibidores directos de la trombina |
EA200900270A1 (ru) * | 2006-08-25 | 2009-08-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Системы регулируемого высвобождения и способ их приготовления |
EP2074112A1 (en) * | 2006-10-10 | 2009-07-01 | Boehringer Ingelheim International GmbH | Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester |
EP2155167A2 (en) * | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
KR20110039261A (ko) * | 2008-07-14 | 2011-04-15 | 베링거 인겔하임 인터내셔날 게엠베하 | 다비가트란을 함유하는 의료용 화합물의 제조 방법 |
JP2012500245A (ja) * | 2008-08-19 | 2012-01-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 経皮的インターベンション心臓カテーテル法のためのダビガトラン |
EA020194B1 (ru) * | 2009-02-02 | 2014-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Лиофилизированный дабигатран |
-
2011
- 2011-02-28 PL PL11704996T patent/PL2542224T3/pl unknown
- 2011-02-28 JP JP2012555381A patent/JP5801826B2/ja not_active Expired - Fee Related
- 2011-02-28 EP EP11704996.5A patent/EP2542224B1/en active Active
- 2011-02-28 EA EA201201202A patent/EA201201202A1/ru unknown
- 2011-02-28 US US13/582,183 patent/US20130052262A1/en not_active Abandoned
- 2011-02-28 PT PT117049965T patent/PT2542224E/pt unknown
- 2011-02-28 CA CA2791561A patent/CA2791561A1/en not_active Abandoned
- 2011-02-28 SI SI201130262T patent/SI2542224T1/sl unknown
- 2011-02-28 WO PCT/EP2011/052919 patent/WO2011107427A1/en active Application Filing
- 2011-02-28 DK DK11704996.5T patent/DK2542224T3/da active
- 2011-02-28 ES ES11704996.5T patent/ES2509117T3/es active Active
-
2012
- 2012-09-02 IL IL221742A patent/IL221742A/en not_active IP Right Cessation
-
2014
- 2014-09-11 CY CY20141100740T patent/CY1115556T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DK2542224T3 (da) | 2014-10-20 |
EA201201202A1 (ru) | 2013-04-30 |
JP2013521244A (ja) | 2013-06-10 |
PT2542224E (pt) | 2014-10-03 |
EP2542224A1 (en) | 2013-01-09 |
CA2791561A1 (en) | 2011-09-09 |
SI2542224T1 (sl) | 2014-10-30 |
EP2542224B1 (en) | 2014-08-13 |
US20130052262A1 (en) | 2013-02-28 |
IL221742A (en) | 2015-09-24 |
WO2011107427A1 (en) | 2011-09-09 |
CY1115556T1 (el) | 2017-01-04 |
ES2509117T3 (es) | 2014-10-17 |
PL2542224T3 (pl) | 2014-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5801826B2 (ja) | ダビガトランエテキシラートを含有する経口用医薬組成物 | |
JP6934932B2 (ja) | アンドロゲン受容体アンタゴニストの固体医薬組成物 | |
KR101840182B1 (ko) | 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온 락테이트 일수화물을 포함한 제약 조성물 | |
US20110300214A1 (en) | Pharmaceutical compositions comprising 5-chloro-n-(-methyl)-2-thiophencarboxamid | |
JP2013521318A (ja) | ダビガトランエテキシラートを含有する医薬組成物 | |
US20120231076A1 (en) | Pharmaceutical compositions comprising rivaroxaban | |
JP6446511B2 (ja) | 非晶質体ソリフェナシン及び抗酸化剤を含有する固形製剤 | |
JP6126456B2 (ja) | 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠 | |
WO2015145462A1 (en) | Pharmaceutical compositions of dabigatran | |
US20140319720A1 (en) | Pharmaceutical compositions comprising rivaroxaban | |
JP6639024B2 (ja) | 化学的な安定性を改善した、非晶質体ソリフェナシン含有製剤 | |
EP2620140A1 (en) | Crizotinib containing compositions | |
JP2017523149A (ja) | エドキサバンの医薬組成物 | |
EP2906203B1 (en) | Effervescent cefdinir formulation | |
EP3860606A1 (en) | Pharmaceutical composition comprising lenvatinib esylate or tosylate | |
WO2019192195A1 (zh) | 含达比加群酯的药物组合物及其制备方法 | |
KR20160014619A (ko) | 공-결정체 형태로 아고멜라틴을 포함하는 아고멜라틴 제형 | |
KR101809886B1 (ko) | 소형화된 클래리트로마이신 경구투여 제제 | |
EP3731822A1 (en) | Oral pharmaceutical compositions of dabigatran | |
KR101956586B1 (ko) | 약제학적 조성물 및 이의 제조방법 | |
EP4279075A1 (en) | A pharmaceutical composition comprising elagolix | |
WO2015199115A1 (ja) | 経口投与用医薬組成物 | |
WO2007029124A2 (en) | Formulations containing pantoprazole free acid and its salts | |
EP3731823A1 (en) | A pharmaceutical formulation for oral administration comprising dabigatran etexilate | |
KR20180060174A (ko) | 덱스란소프라졸을 포함하는 경구용 정제 조성물, 이를 포함하는 경구용 정제 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140207 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20141212 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141216 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150220 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150612 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150818 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150827 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5801826 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |